<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02085694</url>
  </required_header>
  <id_info>
    <org_study_id>001/14</org_study_id>
    <nct_id>NCT02085694</nct_id>
  </id_info>
  <brief_title>Lactobacillus Brevis CD2 Preventing Oral Mucositis</brief_title>
  <official_title>A Pilot Study on the Efficacy of Lactobacillus Brevis CD2 Lozenges in Preventing Oral Mucositis by High-dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot study on efficacy of Lactobacillus CD2 lozenges in preventing oral mucositis (OM) by
      high-dose chemotherapy with autologous hematopoietic stem cell transplantation. To test
      whether the probiotic Lactobacillus brevis CD2 lozenges can reduce the incidence and severity
      of high-dose chemotherapy conditioning regimen induced OM in patients undergoing HSCT.

      Clinical activity will be defined as reduction in the incidence of chemotherapy induced OM in
      the patients undergoing HSCT.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS v4.03 (CTCAE) for evaluation of change in oral mucositis</measure>
    <time_frame>days -14;-7; 0;+7;+14;+21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS v4.03 (CTCAE) to determine the incidence of Grade I and II OM</measure>
    <time_frame>days -14;-7; 0; +7;+14; +21</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Mucositis</condition>
  <arm_group>
    <arm_group_label>Lactobacillus brevis CD2 lozenges</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactobacillus brevis CD2</intervention_name>
    <arm_group_label>Lactobacillus brevis CD2 lozenges</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 65 years

          -  Karnofsky Performance Score â‰¥ 70%.

          -  Confirmed histological diagnosis of multiple myeloma for which HSCT is as approved
             modality of therapy

          -  Patients eligible to receive high-dose chemotherapy as part of conditioning regimen

          -  Concomitant co morbid condition if present, controlled by ongoing treatments (e.g.
             hypertension, diabetes and so on)

          -  Serum creatinine &lt; 1.8mg/dl

          -  Total bilirubin &lt; 2mg/dl

          -  Liver enzymes within three times of normal limit

          -  Expected survival &gt; 6 months.

        Exclusion Criteria:

          -  Pregnant women and lactating mothers

          -  Patients with history of HIV infection

          -  Patients who have taken any other investigational product in last 4 weeks

          -  Patients having untreated symptomatic dental infection

          -  Patients with WHO Grade 3 or 4 oral Mucositis

          -  Other serious concurrent illness

          -  Inconclusive hematological diagnosis

          -  Patients with signs and symptoms of systemic infections

          -  Patient's/guardian's refusal to sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Policlinico Universitario &quot;A. GEMELLI&quot;</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrizia Chiusolo, MD</last_name>
      <phone>0039-0630155300</phone>
      <email>p.chiusolo@rm.unicatt.it</email>
    </contact>
    <contact_backup>
      <last_name>Sabrina Giammarco, MD</last_name>
      <phone>0039-0630155300</phone>
      <email>sabrina_giammarco@libero.it</email>
    </contact_backup>
    <investigator>
      <last_name>Patrizia Chiusolo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sabrina Giammarco, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2014</study_first_submitted>
  <study_first_submitted_qc>March 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2014</study_first_posted>
  <last_update_submitted>March 8, 2014</last_update_submitted>
  <last_update_submitted_qc>March 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of the Sacred Heart</investigator_affiliation>
    <investigator_full_name>sabrina giammarco</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

